Pancreatic cancer from bench to bedside: molecular pathways and treatment options.
In the last forty years the pancreatic cancer treatment has made advances, however; still novel drugs are needed. It is known that the five year survival rate remains around 5%. The best treatment option still remains surgery, if patients are diagnosed early. In the last decade the biology of pancreatic cancer has been vastly explored and novel agents such as; tyrosine kinase agents, or vaccines have been added as a treatment perspective. The big challenge is now to translate this knowledge in better outcomes for patients. In this current review we will present information from pancreatic cancer diagnosis to molecular pathways and treatment options; current and future.
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
Christoforos
C
Kosmidis
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
Konstantinos
K
Sapalidis
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
Efstathios
E
Kotidis
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
Nikolaos
N
Mixalopoulos
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
Paul
P
Zarogoulidis
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
Drosos
D
Tsavlis
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
Sofia
S
Baka
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
Yan-Gao
YG
Man
1 3rd Department of Surgery, AUTH, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece ; 2 Pulmonary Department-Oncology Unit, "G. Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece ; 3 Department of Oncology, Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece ; 4 Research Laboratory and International Collaboration, Bon Secours Cancer Institute, VA, USA.
John
J
Kanellos
Pancreatic cancer (PC); molecular pathways; targeted treatment